article

Skip to content The CRC Digest Females face higher chemotherapy toxicity in metastatic disease Large database analysis confirms females experience more severe side effects from standard mCRC regimens despite similar survival benefits. (European Journal of Cancer) This content is informational only and does not constitute medical advice. Always consult your

Skip to content The CRC Digest ▪ Urinary extracellular vesicles show promise for minimal residual disease detection Study of 160 CRC patients compared urinary EVs to plasma ctDNA for liquid biopsy, finding urinary EVs may offer a non-invasive option for monitoring disease after surgery. (Cancer Science) This content is informational only

Skip to content The CRC Digest RECAST trial compares two first-line regimens with ramucirumab for metastatic colorectal cancer — European Journal of Cancer The randomized phase II WJOG9216G (RECAST) study compared FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer. The trial examines whether the more

Skip to content The CRC Digest FIERCE study assesses safety of trifluridine/tipiracil with radiation before rectal cancer surgery — Clinical Colorectal Cancer The phase Ib FIERCE study evaluated the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage II/III rectal cancer. This trial explores whether this oral

Skip to content The CRC Digest AZUR-4 trial compares neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone — Clinical Colorectal Cancer This phase II randomized study (AZUR-4) is comparing dostarlimab plus CAPEOX versus CAPEOX alone as neoadjuvant treatment in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon

Skip to content The CRC Digest Phase II trial tests pembrolizumab plus chemotherapy in MSS colorectal cancer — Clinical Colorectal Cancer A phase II study evaluated pembrolizumab combined with capecitabine and bevacizumab in patients with microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. This trial addresses the challenge that most colorectal cancers

Skip to content The CRC Digest ▪ SCREENING Blood-based DNA tests show promise for colorectal cancer screening — Critical Reviews in Oncology/Hematology A systematic review and meta-analysis evaluated the diagnostic accuracy of blood-based circulating tumor DNA (ctDNA) tests for detecting advanced colorectal neoplasia in asymptomatic, average-risk populations. The analysis examined how

Skip to content The CRC Digest ▸ TREATMENT Real-world data compares late-line treatment options for metastatic colorectal cancer — ESMO Open A multicenter study compared outcomes of trifluridine/tipiracil (FTD-TPI) plus bevacizumab versus FTD-TPI alone or regorafenib in patients with pretreated metastatic colorectal cancer. The analysis included real-world data on effectiveness and

Skip to content The CRC Digest ◆ TRIAL DATA Chemotherapy alone may be as effective as chemoradiation before rectal cancer surgery — Journal of Clinical Oncology The CONVERT trial compared neoadjuvant chemotherapy with CAPOX (capecitabine and oxaliplatin) versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia. This phase III trial

Skip to content The CRC Digest ◆ TRIAL DATA Long-term results show benefit of chemotherapy after liver metastasis surgery — Journal of Clinical Oncology The JCOG0603 trial compared hepatectomy (liver surgery) followed by mFOLFOX6 chemotherapy versus hepatectomy alone for patients with liver metastases from colorectal cancer. This phase II/III randomized trial